CSF Aβ42 and tau biomarkers in cognitively unimpaired Aβ- middle-aged and older APOE ε4 carriers

YY Lim; N Yassi; L Bransby; S Ayton; RF Buckley; D Eratne; D Velakoulis; QX Li; C Fowler; CL Masters; P Maruff

Journal article

CSF Aβ42 and tau biomarkers in cognitively unimpaired Aβ- middle-aged and older APOE ε4 carriers

YY Lim, N Yassi, L Bransby, S Ayton, RF Buckley, D Eratne, D Velakoulis, QX Li, C Fowler, CL Masters, P Maruff

Neurobiology of Aging | Published : 2023

DOI: 10.1016/j.neurobiolaging.2023.05.009

Abstract

This study aimed to determine the relationship between the apolipoprotein E (APOE) ε4 allele and cerebrospinal fluid (CSF) and neuroimaging biomarkers of Alzheimer's disease, and cognition in cognitively unimpaired (CU) middle-aged adults (n = 82; Mage = 58.2), and in Aβ- CU older adults (n = 71; Mage = 71.8). Aβ- CU middle-aged ε4 carriers showed lower CSF Aβ42 levels, higher levels of CSF total tau (t-tau) and neurofilament light (NfL), and poorer cognitive performance compared to noncarriers (Cohen's d: 0.30–0.56). In Aβ- CU older adults, ε4 carriers also had lower CSF Aβ42 levels and higher levels of CSF t-tau and p-tau181, compared to noncarriers (Cohen's d: 0.65–0.74). In both Aβ- midd..

View full abstract

University of Melbourne Researchers

Nawaf Yassi Author

Scott Ayton Author

Rachel Buckley Author

Dhamidhu Eratne Author

Related Projects (1)

VASCULAR COGNITIVE RISK SCORE: QUANTIFYING THE VASCULAR BURDEN IN ALZHEIMER'S DISEASE

What causes dementia in a patient presenting to a clinic is often uncertain. While there are exciting potential treatments in the pipeline, ..

Grants

Awarded by National Institutes of Health

Funding Acknowledgements

The Healthy Brain Project (healthybrainproject.org.au) is funded by the National Health and Medical Research Council (NHMRC) (GNT1158384, GNT1147465, GNT1111603, GNT1105576, GNT1104273, GNT1171816) , the Alzheimer's Association (AARG-17-591424, AARG-18-591358, AARG-19-643133) , the Dementia Australia Research Foundation, the Yulgilbar Alzheimer's Research Program, and the Charleston Conference for Alzheimer's Disease.Funding for the AIBL study was provided in part by the study partners [Australian Commonwealth Scientific Industrial and Research Organization (CSIRO) , Edith Cowan University (ECU) , Florey Institute, University of Melbourne) , Dementia Australia (DA) , Austin Health, Cogstate Ltd., Sarich Institute] . The study has also received support from the NHMRC.Y.Y. Lim is supported by an NHMRC Career Development Fellowship (GNT1162645) and Emerging Leadership Grant (GNT2009550) . L. Bransby is supported by a Dementia Australia Research Foundation PhD Scholarship. R.F. Buckley is supported by an NIH K99-R00 award (K99AG061238) . D. Eratne is supported by an NHMRC Ideas Grant (GNT1185180) .